Aurora Cannabis Acquires Safari Flower Co. for $26.5M, Boosting EU GMP Capacity for Global Medical Markets
ACB is trading near its 52-week low of $3.07 (15% above the low).
Summary
Aurora Cannabis Inc. announced the acquisition of Safari Flower Company for $26.5 million, significantly expanding its EU GMP certified cultivation capacity to serve growing high-margin international medical cannabis markets.
Key Events · M&A and Partnerships · ACB
-
Strategic Acquisition Announced
Aurora Cannabis acquired Safari Flower Company, an established EU GMP certified cannabis cultivator and manufacturer.
-
Significant Consideration
The aggregate consideration for the acquisition is valued at $26.5 million, including a $2 million contingent cash payment.
-
Expanded EU GMP Capacity
The acquisition provides a 59,000 sq ft EU GMP certified facility, increasing capacity for high-margin international medical cannabis markets.
-
Expected Financial Accretion
The transaction is anticipated to deliver positive Adjusted EBITDA contributions starting in fiscal year 2027.
Analysis · ACB · Life Sciences
This acquisition is a substantial strategic move for Aurora Cannabis, representing a significant portion of its current market capitalization. By acquiring Safari Flower Company, Aurora gains critical EU GMP certified capacity, which is essential for expanding its presence in lucrative international medical cannabis markets like Germany, Australia, Poland, and the UK. The company expects the transaction to be accretive to Adjusted EBITDA by fiscal year 2027, indicating a positive financial impact. The deal structure, involving both cash and stock, suggests a balanced approach to financing this growth initiative. Investors should view this as a clear signal of Aurora's commitment to its medical-first, high-margin international strategy.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 35.7% of the 1838 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ACB was trading at $3.53 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $200.2M. The 52-week trading range was $3.07 to $6.67. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.